- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Respiratory zone.
Displaying page 1 of 1.
EudraCT Number: 2016-002733-30 | Sponsor Protocol Number: 204810 | Start Date*: 2017-03-08 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase I/II, randomised, observer-blind, controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigational R... | |||||||||||||
Medical condition: Healthy pregnant women (Respiratory Syncytial Virus) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000841-12 | Sponsor Protocol Number: 215.1364 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A randomised open label, six way, cross-over scintigraphic evaluation of the effect of inspiratory flow rate on lung and oropharyngeal deposition with the Respimat(R) inhaler vs a Metered Dose Inha... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) is characterised by airflow limitation and bronchial inflammation. Clinically, COPD is characterised by progressive dyspnoea on exertion and intermitten... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000499-24 | Sponsor Protocol Number: 200722 | Start Date*: 2015-02-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies | |||||||||||||
Medical condition: preterm labour and improve neonatal health | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002518-42 | Sponsor Protocol Number: FIBRO-COVID | Start Date*: 2020-07-20 | ||||||||||||||||
Sponsor Name:IDIBELL | ||||||||||||||||||
Full Title: A RANDOMIZED PHASE-II CLINICAL TRIAL TO EVALUATE THE EFFECT OF PIRFENIDONE COMPARED WITH PLACEBO IN PULMONARY FIBROSIS POST-COVID 19: | ||||||||||||||||||
Medical condition: Pulmonary fibrosis induced by SARS-COV2 virus (post-COVID19 pulmonary sequelae) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001671-32 | Sponsor Protocol Number: STS-BDB001-04 | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Staidson (Beijing) Biopharmaceutical Co., Ltd. and Beijing Defengrui Biological Technology Co., Ltd. | |||||||||||||
Full Title: A multi-center, open-label, randomized parallel controlled evaluation on the efficacy and safety of BDB-001 injection in the treatment of progressive severe COVID-19 in phase II | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002312-29 | Sponsor Protocol Number: INOT -27 | Start Date*: 2005-01-10 | |||||||||||
Sponsor Name:INO Therapeutics | |||||||||||||
Full Title: The Effects of Nitric Oxide for Inhalation on the development of chronic lung disease in pre-term infants. | |||||||||||||
Medical condition: Prevention of chronic lung disease in pre-term infants ( gestational age < 29 weeks) with respiratory distress. | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) GB (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000407-41 | Sponsor Protocol Number: FSJD-ESCOKETA-2010 | Start Date*: 2011-07-01 | |||||||||||
Sponsor Name:FUNDACIÓ SANT JOAN DE DEU | |||||||||||||
Full Title: ASSESSMENT OF THE ANALGESIC EFFICACY AND TOLERABILITY OF THE PERIOPERATIVE ASSOCIATION OF KETAMINE WITH OPIATES AFTER POSTERIOR VERTEBRAL FUSION SURGERY IN CHILDREN WITH IDIOPATHIC SCOLIOSIS | |||||||||||||
Medical condition: POSTERIOR VERTEBRAL FUSION SURGERY IN CHILDREN WITH IDIOPATHIC SCOLIOSIS | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003806-18 | Sponsor Protocol Number: IC2014-16 | Start Date*: 2016-03-24 |
Sponsor Name:INSTITUT CURIE | ||
Full Title: IMPROVEMENT OF LOCAL CONTROL IN SKULL BASE AND SPINE CHORDOMAS TREATED BY SURGERY AND PROTONTHERAPY TARGETING HYPOXIC CELLS REVEALED BY POSITRON EMISSION TOMOGRAPHY NITROIMIDAZOLE ([18F]FAZA) PET/C... | ||
Medical condition: Chordomas of the skull base, spine and sacrum | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003559-32 | Sponsor Protocol Number: CPO19001 | Start Date*: 2023-03-16 | ||||||||||||||||
Sponsor Name:PharOS Pharmaceutical Oriented Services Single Member Ltd. | ||||||||||||||||||
Full Title: A Phase III Prospective, Randomized, Multicenter, Double-Blind, Placebo-controlled clinical study to evaluate the efficacy and safety of fixed dose combination (FDC) product Ibuprofen/Paracetamol/P... | ||||||||||||||||||
Medical condition: Temporary relief of cold and flu symptoms, i.e. mild to moderate pain, sore throat, fever and nasal congestion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004647-74 | Sponsor Protocol Number: LPS15834 | Start Date*: 2020-10-27 | |||||||||||
Sponsor Name:Sanofi-Aventis Groupe | |||||||||||||
Full Title: Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters ... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) SE (Ongoing) PT (Completed) ES (Ongoing) BG (Completed) FR (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003249-16 | Sponsor Protocol Number: PML_DOC_1102 | Start Date*: 2012-01-06 | |||||||||||
Sponsor Name:University Hospital of Antwerp | |||||||||||||
Full Title: OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN AS... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001498-21 | Sponsor Protocol Number: A011-14 | Start Date*: 2021-11-11 | |||||||||||
Sponsor Name:Acceleron Pharma Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) W... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004547-77 | Sponsor Protocol Number: RN03-CP-0001 | Start Date*: 2020-06-09 | |||||||||||
Sponsor Name:ReNeuron Ltd | |||||||||||||
Full Title: First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP) | |||||||||||||
Medical condition: Retinitis Pigmentosa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001396-16 | Sponsor Protocol Number: OP0595-6 | Start Date*: 2023-03-29 | |||||||||||||||||||||||||||||||
Sponsor Name:Meiji Seika Pharma Co., Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Ur... | |||||||||||||||||||||||||||||||||
Medical condition: Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated ... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001997-18 | Sponsor Protocol Number: ACHN-490-007 | Start Date*: 2014-02-25 | |||||||||||
Sponsor Name:Achaogen, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Colistin in Patients with Infection due to Carbapenem-Resistant Enterobacteriace... | |||||||||||||
Medical condition: Bloodstream infections (BSI) and nosocomial pneumonia due to carbapenem-resistant Enterobacteriaceae (CRE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) ES (Prematurely Ended) IT (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002862-11 | Sponsor Protocol Number: CXA-NP-11-04 | Start Date*: 2015-07-27 | |||||||||||
Sponsor Name:Cubist Pharmaceuticals GmbH | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated... | |||||||||||||
Medical condition: Ventilated Nosocomial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) EE (Completed) DE (Completed) BE (Completed) LV (Completed) CZ (Completed) HU (Completed) SK (Completed) AT (Completed) GR (Completed) PT (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
